Joseph F. Ruh Named General Counsel And Corporate Secretary At Carestream Health, Inc.

ROCHESTER, N.Y., Feb. 10 — Joseph F. Ruh has been appointed General Counsel and Corporate Secretary at Carestream Health effective immediately. In this role, he will lead the company's worldwide legal organization and is a member of the company's senior executive leadership team.

Ruh brings 30 years of corporate legal experience in working for high-technology organizations with global operations. Formerly Deputy General Counsel and Assistant Corporate Secretary for Carestream—a $2.5 billion healthcare company headquartered in Rochester, N.Y.—he served as the company's lead attorney for its medical and dental businesses. In addition to managing intellectual property and complex commercial transactions, he provided counsel on labor and employment policies and related litigation.

Prior to joining Carestream, Ruh spent 16 years in various roles within Eastman Kodak Company's Legal Department, including serving as lead attorney for Kodak's Internet group, and as division counsel for its digital imaging and motion picture organizations. He also provided worldwide legal support for Kodak's advertising, sponsorship and marketing programs, and intellectual property licensing activities.

Before his career at Kodak, Ruh was in-house counsel at Computer Consoles, Inc., a subsidiary of Nortel, and prior to that he practiced corporate and securities law at the Rochester law firm of Harris Beach.

Ruh holds a Juris Doctorate from the SUNY Buffalo Law School and a B.A. in History and Political Science from the University of Rochester.

A longtime resident of New York State, Joseph Ruh resides in Genesee County with his wife Julia Garver, an attorney in private practice.

Robert Salmon, 585-627-6560, [email protected]

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.